Article
The New England Journal of Medicine has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune thromboc
All News
Article
In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis.
Article
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Dr. John Cush
Tweet
INITIAL Goal is to not miss Red Flag Conditions (Fx, septic or crystal arthritis [all acute monarticular})! Then provide timely Dx & Rx by establishing acute vs chronic, inflam vs noninflam, & articular vs nonarticular.
Dr. John Cush
Tweet
Simple, low-cost strategy to Dx/Prognose GCA using CBC components NLR & PLR. 119 GCA vs 131 non-GCA pts - All CBC biomarkers signif assoc w/ ESR & CRP, but ESR/CRP did not predict mortality over time; YET mortality signif predicted by PLR, NLR, MLR (P value < 0.044) https://t.co/96Q7jDAiWt
Dr. John Cush
Tweet
RHEUM Survey> What is the Sensitivity of the ANA test?
DocXus
Tweet
OPD Spotter
Identify it before the patient even sits
Diagnosis ❓ https://t.co/xM90YEp9jZ
Dr. John Cush
Tweet
British Society of Rheumatology Guideline for Monitoring DMARDs
The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic https://t.co/7KNf6cIjfo
Dr. John Cush
Tweet
I agree that multiple assessments are needed to Dx NP-SLE; but my order of preference (for Dx yield) is: A) Hx c/w cerebritis; B) imaging to r/o other causes; C) CSF IgG index w/ Q albumin
Dr. John Cush
Tweet
The Essential Role of Physician Assistants in Rheumatology
Ready to bring a PA into your rheumatology practice? This blog post breaks down the key facts you need to know about PA training, scope of practice, and the recent changes to the profession's title. https://t.co/0aCTUpWMab
Dr. John Cush
Tweet
Focus on Guidelines https://t.co/Dgu0F5UiNY
Dr. John Cush
Tweet
2018 NHANES population survey of 28,040 individuals, 4168 (14.32%) identified with sleep disorders, and 1589 (4.28%) had #RA. Thus, sleep disorders were significantly associated with increased odds of RA (OR = 1.76, 95% CI: 1.46–2.13, P < 0.001). https://t.co/9O2MsLvwVe https://t.co/cBsm8Jt8Ks
Dr. John Cush
Tweet
APPs in the news (12.5.2025)
Dr. Jack Cush reviews the news and journal reports from https://t.co/V10S4oVFsv, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salaries concerns.
https://t.co/znsjhTqTEv https://t.co/F0eu5w232C
Dr. John Cush
Tweet
RHEUM Survey> What is the goal for every new MSK patient evaluation?
Dr. John Cush
Tweet
Cross-sectional study of 79 743 US primary care practices compared those with and without NPs. NP practices were more likely to be located in lower incomes and lower educational communities. NPs predominated in areas with highest need but lowest supply of PCPs. https://t.co/tSi1OnoSlA
Dr. John Cush
Tweet
QD Clinic: CAR-T Cell Therapy for Lupus
Philip Mease, MD and Cayla Alexander, DNP, ARNP, Seattle, Washington, discuss the case of a patient with lupus who underwent CAR-T cell therapy for her disease. This QD clinic is presented as part of RheumNow's "Mission: APP Partners in https://t.co/WXWOLupWna
Dr. John Cush
Tweet
DMARD Treatment Lags for Minority Groups with Rheumatoid Arthritis
Use of disease-modifying anti-rheumatic drugs (DMARDs) for RA was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, https://t.co/eZOLAN4KVr
Dr. John Cush
Tweet
GESPIC - German SpA study of 252 SpA (139 nr- axSpA, 113 r-axSpA), followed w/ serial Xrays and mSASS Scores over 2 yrs. 80% were on NSAIDs. Higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA https://t.co/MfmzWwvtZx https://t.co/5Fe2AQgkN2
Dr. John Cush
Tweet
Cochrane review of nurse-led care (NLC) in RA, included 14 articles & 3369 RA pts. NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in dz activity and some secondary (self efficacy, pain, QOL) outcomes https://t.co/gd9vbcOR8P
Dr. John Cush
Tweet
Low Dose Naltrexone for Fibromyalgia Pain - Use it or Lose it?
Medscape recently reviewed off-label use of low dose naltrexone (LDN) in fibromyalgia (FM) and found it is deemed effective by some clinicians and patients, but 1) there is no FDA indication for LDN use in FM and 2) https://t.co/RgRRHU9ZRo
